Orphanet Journal of Rare Diseases | Molecular Mechanisms and Clinical Features of Hb Constant Spring Mutation

Recommend:

This systematic review summarizes the molecular basis, pathogenic mechanisms, and clinical manifestations of Hb Constant Spring mutation, covering gene expression regulation, mRNA stability, membrane protein abnormalities, and therapeutic strategies. It provides important insights into the complex phenotypes of this hemoglobinopathy and potential gene therapy approaches.

 

Document Overview

This article titled 'Revisiting hemoglobin constant spring: molecular insights, pathophysiological mechanisms, and clinical perspectives', published in the Orphanet Journal of Rare Diseases, reviews and summarizes the molecular mechanisms, clinical features, and similarities and differences with other α-globin variants of the Hb Constant Spring mutation. The article focuses on the phenotypic differences of this mutation under various genetic backgrounds (e.g., Hb H/CS and homozygous states), as well as current diagnostic and potential gene-editing therapeutic strategies.

Background Knowledge

Hemoglobin Constant Spring (Hb CS) is a hemoglobinopathy caused by a termination codon mutation in the α-globin gene (HBA2:c.427T > C), prevalent in Southeast Asia. The mutation leads to unstable α-globin mRNA, resulting in abnormal hemoglobin synthesis and red blood cell membrane damage. Compound heterozygosity of Hb Constant Spring with α-thalassemia can lead to Hb H/CS disease, with clinical presentations ranging from mild anemia to severe hydrops fetalis. Traditional diagnosis relies on electrophoretic analysis, but the Hb CS peak may be weak or even absent, necessitating molecular testing for confirmation. Current treatment includes blood transfusions and iron chelation, while emerging gene-editing technologies such as prime editing offer promising precision therapies. The article highlights that the clinical diversity of Hb Constant Spring indicates the need for further investigation into its molecular mechanisms, epitranscriptomic changes, and genetic modifiers. Other HBA2 termination codon mutations (e.g., Hb Pakse, Hb Koya Dora) also show similar pathological features, further emphasizing the importance of studying this class of mutations.

 

A practical tool for quickly mapping DNA or RNA sequences to the genome.

Learn More

 

Research Methods and Experiments

The article integrates data from multiple studies, covering mRNA expression analysis, red blood cell morphology, genotype-phenotype correlation, and comparisons of molecular diagnostic techniques. RNA hybridization, high-throughput sequencing, protein interaction analysis, and K-Cl transporter functional assays were employed to further elucidate the molecular defects of Hb Constant Spring and their impact on red blood cell membrane stability. Additionally, the clinical manifestations of Hb Constant Spring were compared with other α-globin variants (e.g., Hb Pakse, Hb Koya Dora), to examine expression differences under various genetic backgrounds.

Key Findings and Perspectives

• Hb Constant Spring mutation (HBA2:c.427T > C) leads to unstable α-globin mRNA with a shortened half-life, resulting in an α-thalassemia-like phenotype.
• The mutant mRNA undergoes translational readthrough into the 3'UTR, interfering with α-complex assembly and reducing hemoglobin synthesis efficiency.
• Compound heterozygosity of Hb Constant Spring with α-thalassemia causes Hb H/CS disease, with clinical severity ranging from mild to severe hemolytic anemia, and some patients requiring long-term transfusions.
• Red blood cell membrane damage, dysregulation of K-Cl co-transporters, and increased membrane rigidity are key mechanisms contributing to disease severity.
• In both bone marrow and peripheral blood, the α/β mRNA ratio is significantly reduced in Hb CS carriers, with higher expression observed in bone marrow than in peripheral blood.
• Upregulation of heat shock proteins (HSPs) and TCP-1 complex proteins (CCTs) may represent part of the cellular stress response.
• Molecular diagnostics (e.g., ARMS-PCR, HRM, Sanger sequencing) are the gold standard for confirming Hb CS, as traditional electrophoresis may miss the diagnosis.
• CRISPR/Cas9-mediated gene editing has successfully corrected the Hb CS mutation in vitro models, but off-target effects and cytotoxicity remain concerns.
• Base editing and Prime editing offer safer therapeutic strategies for Hb CS, enabling precise sequence correction.
• Other HBA2 termination codon mutations (e.g., Hb Pakse, Hb Koya Dora) exhibit similar clinical features, necessitating systematic differential diagnosis.

Significance and Future Directions

This article provides a systematic summary of the molecular mechanisms and clinical heterogeneity of Hb Constant Spring, offering theoretical support for personalized therapeutic strategies and gene-editing interventions. Future research could focus on RNA modifications, epitranscriptomic changes, and AHSP expression regulation to further understand disease modifiers. Meanwhile, gene-editing technologies show great promise in hematopoietic stem cells, but in vivo studies are needed to confirm their long-term stability and safety.

 

A tool to assess the pathogenic potential of gene variants and provide functional analysis references.

Learn More

 

Conclusion

Hb Constant Spring is an unstable hemoglobinopathy caused by a termination codon mutation (TAA→CAA) in the α-globin gene HBA2, commonly found in Southeast Asian populations. The mutation results in unstable mRNA, aberrant translational elongation, red blood cell membrane damage, and exacerbated hemolysis. In compound heterozygous states (e.g., Hb H/CS), clinical manifestations are complex, ranging from mild anemia to severe hydrops fetalis. The article emphasizes the importance of genotype-phenotype correlations and advocates molecular testing as essential for diagnosis. Conventional treatments include blood transfusions and iron chelation, while gene-editing technologies (e.g., Prime editing) are under exploration and may enable precise sequence correction. Future research should investigate regulatory mechanisms such as RNA methylation and AHSP expression changes to support personalized therapy and modifier analysis. This article provides valuable insights for clinical management and development of novel therapies, particularly in the molecular diagnostics and functional studies of rare α-globin variants.

 

Narawich Wongkhammul, Pinyaphat Khamphikham, Supawadee Maneekesorn, and Pimlak Charoenkwan. Revisiting hemoglobin constant spring: molecular insights, pathophysiological mechanisms, and clinical perspectives. Orphanet Journal of Rare Diseases.